Yan Zhang, MD

Quick facts

Phase 2 pipeline

• Polatuzumab Vedotin, Rituximab, Lenalidomide · Oncology
  Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Yan Zhang, MD portfolio CI brief
• Yan Zhang, MD pipeline updates RSS